US 12,274,678 B2
Cannabinoids and uses thereof
David Meiri, Haifa (IL); Elazar Besser, Haifa (IL); Igal Louria-Hayon, Haifa (IL); Paula Berman, Haifa (IL); Gil Moshe Lewitus, Haifa (IL); and Limor Broday, Tel-Aviv (IL)
Assigned to TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, Haifa (IL); and RAMOT AT TEL-AVIV UNIVERSITY LTD., Tel-Aviv (IL)
Appl. No. 17/611,093
Filed by TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, Haifa (IL); and RAMOT AT TEL-AVIV UNIVERSITY LTD., Tel-Aviv (IL)
PCT Filed May 17, 2020, PCT No. PCT/IL2020/050538
§ 371(c)(1), (2) Date Nov. 12, 2021,
PCT Pub. No. WO2020/230145, PCT Pub. Date Nov. 19, 2020.
Claims priority of provisional application 62/848,695, filed on May 16, 2019.
Prior Publication US 2022/0265570 A1, Aug. 25, 2022
Int. Cl. A61K 31/05 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/05 (2013.01) [A61P 35/00 (2018.01)] 23 Claims
 
1. A pharmaceutical composition comprising as an active ingredient a compound referred to as CF1 having the following chemical structure:

OG Complex Work Unit Chemistry
and a pharmaceutically acceptable carrier, wherein at least 5% of the cannabinoid content of the composition is CF1.